Dr. Richard Larivière is a professor in the Department of Medicine at Laval University, and a researcher within the Endocrinology and Nephrology axis of the CHU of Quebec Research Centre. He is also Director of Master’s and PhD programs in Clinical and Biomedical Sciences of the Faculty of Medicine at Laval University. Following his doctoral studies in Clinical Sciences (cardiovascular pharmacology) at the Université de Montréal, and postdoctoral studies in molecular endocrinology at McGill University, Dr. Larivière established himself as a professor-researcher in nephrology and hypertension at L’Hôtel-Dieu de Québec. He is an active member of the Amgen-Laval University Research Chair in Nephrology, a multidisciplinary group of fundamentalist and clinical researchers.
The main objective of Dr. Larivière’s research is to better define the mechanisms of arterial hypertension and remodeling of the blood vessel wall. More specifically, he studies the role of endothelial dysfunction, that is, factors derived from the vascular endothelium in the pathogenesis of arterial hypertension, vascular and renal damage in the case of chronic renal failure, and aging. Over the years, he has demonstrated that an imbalance in endothelial production of vasoconstrictor and vasodilator factors, as well as pro-inflammatory factors, contributes significantly to the increase of arterial pressure and rigidity by stimulating, among other things, hypertrophic remodeling and calcification of the blood vessel wall. He has also demonstrated that endothelial dysfunction can be modulated by various endocrine factors and pharmacological agents, including certain drugs. Dr. Larivière’s research uses a variety of experimental models and human tissue libraries.
10, rue McMahon
Canada G1R 2J6
Data not available
Protective roles of estradiol against vascular oxidative stress in ovariectomized female rats exposed to normoxia or intermittent hypoxiaJournal Article
Acta Physiol (Oxf), 225 (2), 2019.
High calcium, phosphate and calcitriol supplementation leads to an osteocyte-like phenotype in calcified vessels and bone mineralisation defect in uremic ratsJournal Article
J Bone Miner Metab, 37 (2), 2019.
Impact of kidney transplantation on aortic stiffness and aortic stiffness index β0Journal Article
J Hypertens, 37 (7), 2019.
Association of interleukin-6 with aortic stiffness in end-stage renal diseaseJournal Article
J Am Soc Hypertens, 12 (1), 2018.
Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney diseaseJournal Article
J Hypertens, 35 (2), 2017.
Levels of Angiopoietin-Like-2 Are Positively Associated With Aortic Stiffness and Mortality After Kidney TransplantationJournal Article
Am J Hypertens, 30 (4), 2017.
Ablation of Potassium-Chloride Cotransporter Type 3 (Kcc3) in Mouse Causes Multiple Cardiovascular Defects and Isosmotic PolyuriaJournal Article
PLoS One, 11 (5), 2016.
Hypoxia-inducible factor-1 plays a role in phosphate-induced vascular smooth muscle cell calcificationJournal Article
Kidney Int, 90 (3), 2016.
Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcificationJournal Article
Am J Hypertens, 28 (6), 2015.
The impact of warfarin on the rate of progression of aortic stiffness in hemodialysis patients: a longitudinal studyJournal Article
Nephrol Dial Transplant, 29 (11), 2014.
- Hydrochlorothiazide and accelerated CKD-related vascular calcification, from 2023-07-01 to 2025-06-30
- Rôle de la dysfonction endothéliale dans le remodelage et la calcification vasculaire en insuffisance rénale chronique, from 2016-04-01 to 2025-03-31
Recently finished projects
- Accelerated CKD-related vascular calcification: Role of thiazide-type, thiazide-like and loop diuretics, from 2020-10-01 to 2023-05-31
- Proline hydroxylase inhibitors: linking HIF-1 to arterial calcification, from 2019-07-01 to 2021-09-30